Gregory A Vidal - JoVE Visualize

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Nature Communications|March 25, 2018

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomesValeriy Domenyuk, Zoran Gatalica, Radhika Santhanam, et al.

JAMA Oncology|June 14, 2019

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.

Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Nature Communications|March 25, 2018

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomesValeriy Domenyuk, Zoran Gatalica, Radhika Santhanam, et al.

JAMA Oncology|June 14, 2019

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2023

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker ResultsPeter Schmid, Nicholas C Turner, Carlos H Barrios, et al.

Pageof 5